SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Izzy who wrote (4576)6/28/1998 3:55:00 PM
From: Izzy  Read Replies (2) of 6136
 
Today's San Diego Tribune: "Immune Response, Agouron Pharmaceuticals pact has potential." I'm unable to cut/paste the article or retype the whole thing. "However, James McCamant, editor of the Medical Technology Stock Letter in Berkeley, says Agouron stock is "woefully undervalued," in part because of a Merrill Lynch prediction that the annual growth of the HIV market will slow. That estimate is in error, McCamant says. Agouron, which has been trading in the lows $30s, is a buy under $40, he says." That's what I say, too.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News